This site is intended for health professionals only

At the heart of general practice since 1960

pul jul aug2020 cover 80x101px
Read the latest issue online

Independents' Day

Once-daily combination inhaler launched for asthma and COPD

A new once-daily inhaled corticosteroid and long-acting beta-2-agonist combination inhaler for treatment of both asthma and COPD is available on the NHS from this week.

The new inhaler, from manufacturer GlaxoSmithKline, is a combination of fluticasone furoate and vilanterol administered with a dry powder inhaler that is effective for 24 hours.

It is available in high and low-mid ICS dose strengths – 92/22 mcg and 184/22 mcg – for asthma, while only the low-mid, 92/22 mcg dose is approved for use in COPD.

The cost of the Relvar Ellipta inhaler comes in at £27.80 for the low-mid dose and £38.87 for the high-dose version.

This compares with £18 for the Seretide 100 Accuhaler containing fluticasone propionate 100 mcg and salmeterol 50 mcg.

Dr Kevin Gruffydd-Jones, RCGP respiratory clinical lead and a GP in Box, Wiltshire, said the inhaler could offer a potential advantage in terms of improved adherence for some patients with COPD in particular.

Dr Gruffydd-Jones told Pulse: ‘I think it’s a very welcome new addition to the respiratory drugs we have. There are potential cost savings for the NHS with its use in some patients, especially among patients with COPD. It appears to be a very user friendly device and for some patients this may be an advantage.’

Readers' comments (2)

  • Vinci Ho

    Quick glance on phase III trial evidence . The dose being tested was 92/22 emitted dose ( equivalent to 100 mcg fluticasone furorate and 25 mg vilanterol).
    92/22 once a day is compatible with Seretide 250 Acuhaler twice a day IN ASTHMA . Could not find the evidence comparing 184/22 once a day with Seretide 500 Acuhaler BD IN ASTHMA.
    92/22 once a day is compatible with Seretide 500 Acuhaler twice a day IN COPD. And there was no significance between 92/22 and the higher dose IN COPD, hence not granted licence.

    Unsuitable or offensive? Report this comment

  • Vinci Ho

    Yes . Also interesting politics is involved. I wonder how GSK will promote this drug in China given the recent scandal in China. Also this drug will be head to head to its well selling product Seretide. I think we should wait a bit more for independent reviews.

    Unsuitable or offensive? Report this comment

  • This comment has been moderated

Have your say